Published June 17, 2026 in GeekWire
Article by Kurt Schlosser
Article Excerpt
Bainbridge Island, Wash.-based Solius Labs announced $23 million in Series A funding on Wednesday along with the launch of the Solius Pro: a $2,995 UVB (Ultraviolet B) light therapy device for home and professional use.
The device, which hangs on a wall and is about the size of a large laptop computer, scans a user’s skin to calculate a personalized dose of UVB light at a targeted 293-nanometer wavelength. Solius Pro delivers light therapy to the user’s back in a single weekly session of less than five minutes, and is controlled via a smartphone app.
“UVB is not new,” Solius CEO Chris Kiple told GeekWire. “We’re just the first that has made UVB safe and usable and accessible anytime in an efficient way.”
The Food and Drug Administration cleared the Solius Pro as a Class II medical device under a product code — SGZ — created for the technology, according to the company. That clearance specifically covers stimulating the body’s vitamin D production in people 22 and older, according to FDA filings.
UVB light therapy has traditionally been available in dermatology clinics, where it’s typically used to treat skin conditions including eczema, psoriasis and vitiligo.
The skin-scanning system is patent-pending and central to Solius’s safety claim. Because UVB response varies significantly by skin type, a personalized dose is essential — too little delivers no benefit, too much risks skin damage. Kiple said Solius is the first company to develop a sensor that can calculate that dose automatically, without a clinician present.